<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00480870</url>
  </required_header>
  <id_info>
    <org_study_id>CEP nº051/99</org_study_id>
    <nct_id>NCT00480870</nct_id>
  </id_info>
  <brief_title>The Effect of Anticholinesterase Drugs on Sleep in Alzheimer's Disease Patients</brief_title>
  <acronym>ACHALZSLEEP</acronym>
  <official_title>The Effect of Anticholinesterase Drugs on Sleep in Alzheimer's Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Associacao Fundo de Incentivo a Psicofarmcologia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Associacao Fundo de Incentivo a Psicofarmcologia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of the anticholinesterase drug
      donepezil on sleep in Alzheimer disease patients. Sleep structure and respiratory parameters
      will be analyzed by polysomnography.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Central acting cholinesterase inhibitors are the first primary pharmacological treatment
      approved for Alzheimer disease, of which donepezil is the most frequently used. Multicenter
      studies have found little toxicity, and its side effects (diarrhea, nausea, vomiting,
      nightmares, among others) are mild and transient. According to the literature, cholinergic
      active drugs may be expected to affect REM (rapid eye movement) sleep. Another possible
      effect is related to respiratory parameters in patients with Alzheimer disease and
      obstructive sleep apnea. In fact, cholinergic activity influences the upper airway opening
      via central and peripheral mechanisms.

      Intervention: Patients will be administered donepezil or placebo. The study has a randomized,
      double-blind placebo-controlled design. Complete polysomnography with REM sleep EEG spectral
      analysis and ADAS-cog scoring will be performed at baseline and after 3 and 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1999</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Polysomnography parameters: sleep structure, respiratory, limb movements</measure>
    <time_frame>onset, 3 and 6 months of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain magnetic resonance imaging</measure>
    <time_frame>onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>laboratory tests: hematological evaluation, creatinine, vitamin B12-folic acid, thyroid hormones, GOT, GPT, GGT, bilirubin, fasting glycemia, venereal disease research test and urine sediment</measure>
    <time_frame>onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>electroencephalogram</measure>
    <time_frame>onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-mental state examination</measure>
    <time_frame>onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IDATE</measure>
    <time_frame>onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency bands of scalp EEG areas: overall (average of all electrodes), frontal (F3, F4, F7, F8, Fz), temporal (T3, T4, T5, T6), parietal (P3, P4, Pz), central (C3, C4, Cz), and occipital (O1, O2, Oz).</measure>
    <time_frame>onset, 3 and 6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADAS-cog scores</measure>
    <time_frame>onset, 3 and 6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Dementia Rating</measure>
    <time_frame>onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EEG slowing ratio</measure>
    <time_frame>onset, 3 and 6 monthes of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Sleep Apnea, Obstructive</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donepezil treated Alzheimer patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo treated Alzheimer patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>donepezil</intervention_name>
    <description>donepezil 5 mg 1 p / day for 1 month and 2p / day for 5 months on.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 1p / day for 1 month and 2 / day for 5 months on</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Alzheimer's disease based on the probability criteria of the Alzheimer's
             Disease and Related Disorders Association

          -  Rated 1 and 2 (mild to moderate level) on the Brazilian version of the Clinical
             Dementia Rating

        Exclusion Criteria:

          -  Other causes of dementia

          -  Other severe medical or psychiatric disease

          -  Clinical indication of psychoactive drugs other than experimental drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter AS Moraes, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associação Fundo de Incentivo a Psicofarmacologia - AFIP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto do Sono</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04020-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Rosa A, Poyares D, Moraes W, Cintra F. Methodology in clinical sleep research. Cell Mol Life Sci. 2007 May;64(10):1244-53. Review.</citation>
    <PMID>17364137</PMID>
  </reference>
  <reference>
    <citation>Lucchesi LM, Pradella-Hallinan M, Lucchesi M, Moraes WA. [Sleep in psychiatric disorders]. Rev Bras Psiquiatr. 2005 May;27 Suppl 1:27-32. Epub 2005 Jul 28. Review. Portuguese.</citation>
    <PMID>16082452</PMID>
  </reference>
  <results_reference>
    <citation>Moraes Wdos S, Poyares DR, Guilleminault C, Ramos LR, Bertolucci PH, Tufik S. The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double-blind placebo-controlled study. Sleep. 2006 Feb;29(2):199-205.</citation>
    <PMID>16494088</PMID>
  </results_reference>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2007</study_first_submitted>
  <study_first_submitted_qc>May 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2007</study_first_posted>
  <last_update_submitted>December 3, 2007</last_update_submitted>
  <last_update_submitted_qc>December 3, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2007</last_update_posted>
  <responsible_party>
    <name_title>Walter Andre dos Santos Moraes/ MD PhD</name_title>
    <organization>AFIP</organization>
  </responsible_party>
  <keyword>Alzheimer</keyword>
  <keyword>polysomnography</keyword>
  <keyword>REM sleep</keyword>
  <keyword>donepezil</keyword>
  <keyword>sleep apnea</keyword>
  <keyword>oxygen saturation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
    <mesh_term>Cholinesterase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

